{"id":"W4386002127","doi":"10.1093/oncolo/oyad210","title":"Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type <i>RAS</i> Metastatic Colorectal Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Array BioPharma; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Panitumumab; Medicine; Rash; Colorectal cancer; Internal medicine; Adverse effect; Tolerability; Phases of clinical research; MEK inhibitor; Oncology; Epidermal growth factor receptor; EGFR inhibitors; KRAS; MAPK/ERK pathway; Gastroenterology; Cancer; Clinical trial; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001537688,0.001969959,0.001766701,0.0004826843,0.0003947468,0.0009751915,0.0009375817,0.001217095,0.003172034],"category_scores_gemma":[0.000845086,0.0008474132,0.0009238538,0.0004342561,0.0009963518,0.001004632,0.0003368763,0.003591943,0.000877935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001263388,"about_ca_system_score_gemma":0.001808882,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001325814,"about_ca_topic_score_gemma":0.002515774,"domain_scores_codex":[0.999611,0.0001664272,0.00002328143,0.00007460851,0.00003732837,0.00008746759],"domain_scores_gemma":[0.9992235,0.00009461412,0.0001620894,0.00006671043,0.00004967323,0.0004033975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7496144,0.1102017,0.005149358,0.000566798,0.001065924,0.0002117206,0.0002881645,0.003213327,0.06407078,0.0002707866,0.002750577,0.0625966],"study_design_scores_gemma":[0.5545768,0.4271794,0.007958307,0.00002756619,0.0003108437,0.0002517035,0.00004630887,0.001336216,0.006413615,0.0001594599,0.001710882,0.00002886797],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930374,0.001105405,0.0006234572,0.0003059902,0.00009438901,0.002549117,0.0007940317,0.00008552983,0.001404654],"genre_scores_gemma":[0.9908161,0.001042776,0.00148212,0.0005619897,0.0001135665,0.002327088,0.001819259,0.00002902282,0.00180811],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003172034,"threshold_uncertainty_score":0.01061153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08035892614467251,"score_gpt":0.3976185822566396,"score_spread":0.3172596561119671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}